Simon TA, Suissa S, Skovron ML, Frisell T, Askling J, Michaud K, Pedro S, Strangfeld A, Meissner Y, Boers M, Hoffman V, Dominique A, Gomez A, Hochberg MC. Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: results from a 10-year international post-marketing study. Semin Arthritis Rheum. 2024 Feb;64:152313. doi: 10.1016/j.semarthrit.2023.152313
Lioudis M, Zhou X, Davenport E, Nunna S, Krasa HB, Oberdhan D, Fernandes AW. Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis. BMC Neurol. 2023 Jun 22;24:182. doi: 10.1186/s12882-023-03247-6
Giner-Soriano M, Marsal JR, Gomez-Lumbreras A, Morros R. Risk of ischaemic stroke associated with antiepileptic drugs: a population-based case-control study in Catalonia. BMC Neurol. 2021 May 24;21(1):208. doi: 10.1186/s12883-021-02237-1
Giner-Soriano M, Marsal JR, Gomez-Lumbreras A, Morros R. Risk of ischaemic stroke associated with antiepileptic drugs: a population-based case-control study in Catalonia. BMC Neurol. 2021 May 24;21(1):208. doi: 10.1186/s12883-021-02237-1
Matlis S, Boric K, Chu CJ, Kramer MA. Robust disruptions in electroencephalogram cortical oscillations and large-scale functional networks in autism. BMC Neurol. 2015 Jun 27;15:97. doi: 10.1186/s12883-015-0355-8.
Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT. Does switching anti-TNFα biologic agents represent an effective option in childhood chronic uveitis: the evidence from a systematic review and meta-analysis approach. Semin Arthritis Rheum. 2014 Aug;44(1):39-46. doi: 10.1016/j.semarthrit.2014.03.001
Thyagarajan (Hoffman) V, Norman H, Alexander KA, Napalkov P, Enger C. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients. Semin Arthritis Rheum. 2012 Dec;42(3):223-33. doi: 10.1016/j.semarthrit.2012.05.004